Ranking · Trials
Recruiting clinical trials
Interventional studies currently RECRUITING whose conditions map to this cancer or its descendants.
Computedci-recruiting-trials-v1unit: counthigher = betterAll metrics
| Rank | Δ | Cancer | Recruiting clinical trials (count) | Percentile | Confidence | Sources | Why #n? |
|---|---|---|---|---|---|---|---|
| 1 | = | Malignant Neoplasm | 10,885 | 100 | Medium confidence | clinicaltrials | inputs
ranking row 2582609 |
| 2 | = | Carcinoma | 3,959 | 99.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582610 |
| 3 | = | Malignant Digestive System Neoplasm | 2,361 | 99.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582611 |
| 4 | = | Secondary Malignant Neoplasm | 2,317 | 99.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582612 |
| 5 | = | Malignant Neoplasm of Unknown Primary | 2,257 | 99.7 | Medium confidence | clinicaltrials | inputs
ranking row 2582613 |
| 6 | = | Carcinoma of Unknown Primary | 2,255 | 99.6 | Medium confidence | clinicaltrials | inputs
ranking row 2582614 |
| 7 | = | Malignant Genitourinary System Neoplasm | 1,928 | 99.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582615 |
| 8 | = | Malignant Reproductive System Neoplasm | 1,543 | 99.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582616 |
| 9 | = | Adenocarcinoma | 1,518 | 99.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582617 |
| 10 | = | Malignant Thoracic Neoplasm | 1,493 | 99.3 | Medium confidence | clinicaltrials | inputs
ranking row 2582618 |
| 11 | = | Malignant Lung Neoplasm | 1,428 | 99.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582620 |
| 11 | = | Malignant Respiratory System Neoplasm | 1,428 | 99.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582619 |
| 13 | = | Malignant Breast Neoplasm | 1,396 | 99.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582621 |
| 14 | = | Lymphoma | 1,285 | 99 | Medium confidence | clinicaltrials | inputs
ranking row 2582622 |
| 15 | = | Lymphoid Neoplasm | 1,269 | 98.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582623 |
| 16 | = | Digestive System Carcinoma | 1,216 | 98.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582624 |
| 17 | = | Non-Hodgkin Lymphoma | 1,128 | 98.7 | Medium confidence | clinicaltrials | inputs
ranking row 2582625 |
| 18 | = | Lung Carcinoma | 1,127 | 98.7 | Medium confidence | clinicaltrials | inputs
ranking row 2582626 |
| 19 | = | B-Cell Malignant Neoplasm | 1,078 | 98.6 | Medium confidence | clinicaltrials | inputs
ranking row 2582627 |
| 20 | = | Leukemia | 1,011 | 98.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582628 |
| 21 | = | Malignant Intestinal Neoplasm | 938 | 98.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582629 |
| 22 | = | Lung Non-Small Cell Carcinoma | 924 | 98.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582631 |
| 22 | = | Non-Small Cell Carcinoma | 924 | 98.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582630 |
| 24 | = | Malignant Large Intestinal Neoplasm | 913 | 98.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582632 |
| 25 | = | B-Cell Non-Hodgkin Lymphoma | 905 | 98.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582633 |
| 26 | = | Malignant Colorectal Neoplasm | 882 | 98 | Medium confidence | clinicaltrials | inputs
ranking row 2582634 |
| 27 | = | Malignant Female Reproductive System Neoplasm | 819 | 98 | Medium confidence | clinicaltrials | inputs
ranking row 2582635 |
| 28 | = | Digestive System Adenocarcinoma | 800 | 97.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582636 |
| 29 | = | Hepatopancreatobiliary Carcinoma | 791 | 97.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582637 |
| 30 | = | Malignant Male Reproductive System Neoplasm | 784 | 97.7 | Medium confidence | clinicaltrials | inputs
ranking row 2582638 |
| 31 | = | Genitourinary System Carcinoma | 778 | 97.6 | Medium confidence | clinicaltrials | inputs
ranking row 2582640 |
| 31 | = | Malignant Head and Neck Neoplasm | 778 | 97.6 | Medium confidence | clinicaltrials | inputs
ranking row 2582639 |
| 33 | = | Acute Leukemia | 760 | 97.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582641 |
| 34 | = | Malignant Prostate Neoplasm | 744 | 97.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582642 |
| 35 | = | Malignant Hepatobiliary Neoplasm | 665 | 97.3 | Medium confidence | clinicaltrials | inputs
ranking row 2582643 |
| 36 | = | Malignant Bone Marrow Neoplasm | 591 | 97.3 | Medium confidence | clinicaltrials | inputs
ranking row 2582644 |
| 37 | = | Myeloproliferative Neoplasm | 552 | 97.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582645 |
| 38 | = | Head and Neck Carcinoma | 533 | 97.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582646 |
| 39 | = | Malignant Nervous System Neoplasm | 532 | 97 | Medium confidence | clinicaltrials | inputs
ranking row 2582647 |
| 40 | = | Malignant Liver Neoplasm | 530 | 96.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582648 |
| 41 | = | Squamous Cell Carcinoma | 517 | 96.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582649 |
| 42 | = | Malignant Pancreatic Neoplasm | 506 | 96.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582650 |
| 43 | = | Myeloid Leukemia | 498 | 96.7 | Medium confidence | clinicaltrials | inputs
ranking row 2582651 |
| 44 | = | Breast Carcinoma | 477 | 96.6 | Medium confidence | clinicaltrials | inputs
ranking row 2582652 |
| 45 | = | Primary Malignant Liver Neoplasm | 471 | 96.6 | Medium confidence | clinicaltrials | inputs
ranking row 2582653 |
| 46 | = | Acute Myeloid Leukemia | 466 | 96.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582655 |
| 46 | = | Lymphoid Leukemia | 466 | 96.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582654 |
| 48 | = | Malignant Urinary System Neoplasm | 464 | 96.3 | Medium confidence | clinicaltrials | inputs
ranking row 2582656 |
| 49 | = | Liver Carcinoma | 463 | 96.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582657 |
| 50 | = | Malignant Uterine Neoplasm | 455 | 96.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582658 |
| 51 | = | Malignant Central Nervous System Neoplasm | 453 | 96.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582659 |
| 52 | = | Multiple Myeloma | 414 | 96 | Medium confidence | clinicaltrials | inputs
ranking row 2582660 |
| 53 | = | Hepatocellular Carcinoma | 412 | 95.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582661 |
| 54 | = | Pancreatobiliary Carcinoma | 403 | 95.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582662 |
| 55 | = | Mature B-Cell Non-Hodgkin Lymphoma | 401 | 95.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582663 |
| 56 | = | Malignant Ovarian Neoplasm | 385 | 95.7 | Medium confidence | clinicaltrials | inputs
ranking row 2582664 |
| 57 | = | Breast Adenocarcinoma | 381 | 95.6 | Medium confidence | clinicaltrials | inputs
ranking row 2582665 |
| 58 | = | Sarcoma | 364 | 95.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582666 |
| 59 | = | Malignant Gastric Neoplasm | 351 | 95.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582667 |
| 60 | = | Urinary System Carcinoma | 350 | 95.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582668 |
| 61 | = | Precursor Lymphoid Neoplasm | 345 | 95.3 | Medium confidence | clinicaltrials | inputs
ranking row 2582669 |
| 62 | = | Acute Lymphoblastic Leukemia | 331 | 95.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582670 |
| 63 | = | Malignant Neck Neoplasm | 330 | 95.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582671 |
| 64 | = | Malignant Glioma | 316 | 95.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582672 |
| 65 | = | Melanoma | 314 | 95 | Medium confidence | clinicaltrials | inputs
ranking row 2582673 |
| 66 | = | Head and Neck Squamous Cell Carcinoma | 313 | 94.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582674 |
| 67 | = | Invasive Malignant Neoplasm | 302 | 94.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582675 |
| 68 | = | Invasive Carcinoma | 301 | 94.7 | Medium confidence | clinicaltrials | inputs
ranking row 2582676 |
| 68 | = | Malignant Esophageal Neoplasm | 301 | 94.7 | Medium confidence | clinicaltrials | inputs
ranking row 2582677 |
| 70 | = | Breast Carcinoma by Gene Expression Profile | 295 | 94.6 | Medium confidence | clinicaltrials | inputs
ranking row 2582678 |
| 71 | = | Anaplastic Malignant Neoplasm | 292 | 94.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582679 |
| 72 | = | Endocrine Carcinoma | 291 | 94.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582681 |
| 72 | = | Malignant Endocrine Neoplasm | 291 | 94.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582680 |
| 74 | = | WHO Grade 4 Glioma | 288 | 94.3 | Medium confidence | clinicaltrials | inputs
ranking row 2582682 |
| 75 | = | Pancreatic Carcinoma | 283 | 94.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582683 |
| 76 | = | Malignant Cervical Neoplasm | 279 | 94.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582684 |
| 77 | = | Adult-Type Diffuse Glioma | 275 | 94 | Medium confidence | clinicaltrials | inputs
ranking row 2582685 |
| 78 | = | Malignant Urinary Tract Neoplasm | 270 | 94 | Medium confidence | clinicaltrials | inputs
ranking row 2582686 |
| 79 | = | High Grade Astrocytic Tumor | 265 | 93.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582687 |
| 80 | = | Neuroendocrine Carcinoma | 261 | 93.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582688 |
| 81 | = | Glioblastoma | 260 | 93.7 | Medium confidence | clinicaltrials | inputs
ranking row 2582689 |
| 82 | = | Esophageal and Gastroesophageal Junction Carcinoma | 253 | 93.7 | Medium confidence | clinicaltrials | inputs
ranking row 2582690 |
| 83 | = | Malignant Anorectal Neoplasm | 248 | 93.6 | Medium confidence | clinicaltrials | inputs
ranking row 2582691 |
| 84 | = | Male Reproductive System Carcinoma | 240 | 93.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582692 |
| 84 | = | Neck Carcinoma | 240 | 93.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582693 |
| 86 | = | Intestinal Carcinoma | 235 | 93.3 | Medium confidence | clinicaltrials | inputs
ranking row 2582694 |
| 87 | = | Triple-Negative Breast Carcinoma | 234 | 93.3 | Medium confidence | clinicaltrials | inputs
ranking row 2582695 |
| 88 | = | Malignant Kidney Neoplasm | 231 | 93.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582696 |
| 89 | = | Prostate Carcinoma | 230 | 93.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582697 |
| 90 | = | Female Reproductive System Carcinoma | 229 | 93 | Medium confidence | clinicaltrials | inputs
ranking row 2582698 |
| 91 | = | Malignant Uterine Corpus Neoplasm | 226 | 92.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582699 |
| 92 | = | Malignant Pharyngeal Neoplasm | 222 | 92.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582700 |
| 93 | = | Malignant Rectal Neoplasm | 215 | 92.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582701 |
| 94 | = | Exocrine Pancreas Carcinoma | 210 | 92.7 | Medium confidence | clinicaltrials | inputs
ranking row 2582703 |
| 94 | = | Malignant Exocrine Pancreas Neoplasm | 210 | 92.7 | Medium confidence | clinicaltrials | inputs
ranking row 2582702 |
| 94 | = | Pancreatic Adenocarcinoma | 210 | 92.7 | Medium confidence | clinicaltrials | inputs
ranking row 2582704 |
| 97 | = | Malignant Solid Neoplasm | 209 | 92.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582705 |
| 97 | = | Small Cell Neuroendocrine Carcinoma | 209 | 92.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582706 |
| 99 | = | Chronic Leukemia | 207 | 92.3 | Medium confidence | clinicaltrials | inputs
ranking row 2582707 |
| 99 | = | Malignant Biliary Tract Neoplasm | 207 | 92.3 | Medium confidence | clinicaltrials | inputs
ranking row 2582708 |
| 101 | = | Lung Neuroendocrine Carcinoma | 206 | 92.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582709 |
| 102 | = | Malignant Endometrial Neoplasm | 203 | 92.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582710 |
| 103 | = | Lung Small Cell Carcinoma | 202 | 92 | Medium confidence | clinicaltrials | inputs
ranking row 2582711 |
| 104 | = | Throat Carcinoma | 201 | 91.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582712 |
| 105 | = | Kidney Carcinoma | 200 | 91.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582713 |
| 106 | = | Myelodysplastic Syndrome | 196 | 91.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582714 |
| 107 | = | Colorectal Carcinoma | 194 | 91.7 | Medium confidence | clinicaltrials | inputs
ranking row 2582715 |
| 108 | = | Urinary System Adenocarcinoma | 193 | 91.6 | Medium confidence | clinicaltrials | inputs
ranking row 2582716 |
| 109 | = | Pharyngeal Carcinoma | 191 | 91.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582717 |
| 109 | = | Renal Cell Carcinoma | 191 | 91.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582718 |
| 111 | = | Diffuse Large B-Cell Lymphoma | 190 | 91.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582720 |
| 111 | = | Malignant Soft Tissue Neoplasm | 190 | 91.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582719 |
| 113 | = | Soft Tissue Sarcoma | 188 | 91.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582721 |
| 114 | = | Esophageal Carcinoma | 178 | 91.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582722 |
| 115 | = | Malignant Bladder Neoplasm | 177 | 91.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582723 |
| 116 | = | Urinary Tract Carcinoma | 176 | 91 | Medium confidence | clinicaltrials | inputs
ranking row 2582724 |
| 117 | = | Non-Hodgkin Lymphoma by Clinical Course | 172 | 90.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582725 |
| 118 | = | Malignant Skin Neoplasm | 171 | 90.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582726 |
| 119 | = | Childhood Malignant Neoplasm | 158 | 90.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582727 |
| 120 | = | Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | 144 | 90.7 | Medium confidence | clinicaltrials | inputs
ranking row 2582728 |
| 121 | = | Malignant Ovarian Epithelial Tumor | 140 | 90.6 | Medium confidence | clinicaltrials | inputs
ranking row 2582729 |
| 121 | = | Ovarian Carcinoma | 140 | 90.6 | Medium confidence | clinicaltrials | inputs
ranking row 2582730 |
| 123 | = | Malignant Nasopharyngeal Neoplasm | 139 | 90.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582731 |
| 124 | = | Biliary Tract Carcinoma | 137 | 90.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582732 |
| 125 | = | Lymphoma by Site | 133 | 90.3 | Medium confidence | clinicaltrials | inputs
ranking row 2582733 |
| 126 | = | Nasopharyngeal Carcinoma | 131 | 90.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582734 |
| 127 | = | Pancreatic Ductal Adenocarcinoma | 129 | 90.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582735 |
| 128 | = | T-Cell Non-Hodgkin Lymphoma | 128 | 90 | Medium confidence | clinicaltrials | inputs
ranking row 2582736 |
| 129 | = | Gastroesophageal Junction Carcinoma | 125 | 90 | Medium confidence | clinicaltrials | inputs
ranking row 2582738 |
| 129 | = | Malignant Bile Duct Neoplasm | 125 | 90 | Medium confidence | clinicaltrials | inputs
ranking row 2582737 |
| 131 | = | Chronic Lymphocytic Leukemia | 124 | 89.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582740 |
| 131 | = | Transitional Cell Carcinoma | 124 | 89.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582739 |
| 133 | = | Castration-Resistant Prostate Carcinoma | 123 | 89.7 | Medium confidence | clinicaltrials | inputs
ranking row 2582741 |
| 134 | = | Gastroesophageal Junction Adenocarcinoma | 122 | 89.6 | Medium confidence | clinicaltrials | inputs
ranking row 2582742 |
| 135 | = | Cholangiocarcinoma | 119 | 89.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582744 |
| 135 | = | Esophageal Squamous Cell Carcinoma | 119 | 89.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582743 |
| 135 | = | Intraductal Papillary Neoplasm of the Bile Duct | 119 | 89.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582745 |
| 138 | = | Malignant Colon Neoplasm | 117 | 89.3 | Medium confidence | clinicaltrials | inputs
ranking row 2582747 |
| 138 | = | Urothelial Carcinoma | 117 | 89.3 | Medium confidence | clinicaltrials | inputs
ranking row 2582746 |
| 140 | = | Malignant Brain Neoplasm | 112 | 89.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582749 |
| 140 | = | Malignant Intracranial Neoplasm | 112 | 89.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582748 |
| 142 | = | Follicular Lymphoma | 107 | 88.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582750 |
| 143 | = | B Lymphoblastic Leukemia/Lymphoma | 103 | 88.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582751 |
| 143 | = | Indolent Non-Hodgkin Lymphoma | 103 | 88.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582752 |
| 145 | = | B Acute Lymphoblastic Leukemia | 95 | 88.7 | Medium confidence | clinicaltrials | inputs
ranking row 2582753 |
| 146 | = | Gastric Carcinoma | 93 | 88.6 | Medium confidence | clinicaltrials | inputs
ranking row 2582754 |
| 146 | = | Mantle Cell Lymphoma | 93 | 88.6 | Medium confidence | clinicaltrials | inputs
ranking row 2582755 |
| 146 | = | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | 93 | 88.6 | Medium confidence | clinicaltrials | inputs
ranking row 2582756 |
| 149 | = | Aggressive Non-Hodgkin Lymphoma | 92 | 88.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582758 |
| 149 | = | Malignant Thyroid Gland Neoplasm | 92 | 88.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582757 |
| 151 | = | Hodgkin Lymphoma | 90 | 88.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582759 |
| 152 | = | Indolent B-Cell Non-Hodgkin Lymphoma | 84 | 88.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582760 |
| 153 | = | Cervical Carcinoma | 80 | 88.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582763 |
| 153 | = | Malignant Head and Neck Mucosal Neoplasm | 80 | 88.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582762 |
| 153 | = | Primitive Neuroectodermal Tumor | 80 | 88.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582761 |
| 156 | = | Head and Neck Mucosal Squamous Cell Carcinoma | 78 | 87.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582764 |
| 157 | = | Clear Cell Adenocarcinoma | 77 | 87.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582766 |
| 157 | = | Malignant Lip and Oral Cavity Neoplasm | 77 | 87.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582765 |
| 157 | = | Malignant Oropharyngeal Neoplasm | 77 | 87.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582767 |
| 160 | = | Malignant Fallopian Tube Neoplasm | 76 | 87.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582769 |
| 160 | = | Malignant Peritoneal and Retroperitoneal Neoplasm | 76 | 87.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582768 |
| 162 | = | Neuroblastic Tumor | 75 | 87.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582770 |
| 162 | = | Neuroblastoma | 75 | 87.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582771 |
| 164 | = | Bladder Carcinoma | 74 | 87.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582773 |
| 164 | = | Female Reproductive System Adenocarcinoma | 74 | 87.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582772 |
| 166 | = | HER2-Positive Breast Carcinoma | 73 | 87.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582775 |
| 166 | = | Malignant Musculoskeletal Neoplasm | 73 | 87.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582774 |
| 168 | = | Infection-Related Malignant Neoplasm | 71 | 86.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582776 |
| 169 | = | Myelodysplastic/Myeloproliferative Neoplasm | 70 | 86.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582777 |
| 169 | = | Virus-Related Malignant Neoplasm | 70 | 86.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582778 |
| 171 | = | Gastric Adenocarcinoma | 69 | 86.7 | Medium confidence | clinicaltrials | inputs
ranking row 2582780 |
| 171 | = | Skin Carcinoma | 69 | 86.7 | Medium confidence | clinicaltrials | inputs
ranking row 2582779 |
| 173 | = | Small Lymphocytic Lymphoma | 67 | 86.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582781 |
| 174 | = | Invasive Prostate Carcinoma | 65 | 86.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582782 |
| 175 | = | Colorectal Adenocarcinoma | 64 | 86.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582783 |
| 176 | = | Prostate Adenocarcinoma | 62 | 86.3 | Medium confidence | clinicaltrials | inputs
ranking row 2582784 |
| 177 | = | Marginal Zone Lymphoma | 61 | 86.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582785 |
| 178 | = | Clear Cell Renal Cell Carcinoma | 60 | 86.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582786 |
| 179 | = | Invasive Bladder Carcinoma | 59 | 86.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582787 |
| 180 | = | Malignant Muscle Neoplasm | 58 | 86 | Medium confidence | clinicaltrials | inputs
ranking row 2582788 |
| 180 | = | Myosarcoma | 58 | 86 | Medium confidence | clinicaltrials | inputs
ranking row 2582789 |
| 180 | = | Osteosarcoma | 58 | 86 | Medium confidence | clinicaltrials | inputs
ranking row 2582790 |
| 183 | = | Malignant Oral Cavity Neoplasm | 57 | 85.7 | Medium confidence | clinicaltrials | inputs
ranking row 2582791 |
| 184 | = | Aggressive B-Cell Non-Hodgkin Lymphoma | 56 | 85.7 | Medium confidence | clinicaltrials | inputs
ranking row 2582792 |
| 184 | = | Oropharyngeal Carcinoma | 56 | 85.7 | Medium confidence | clinicaltrials | inputs
ranking row 2582793 |
| 186 | = | Encapsulated Glioma | 55 | 85.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582795 |
| 186 | = | Malignant Mesothelioma | 55 | 85.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582794 |
| 188 | = | Central Nervous System Lymphoma | 54 | 85.3 | Medium confidence | clinicaltrials | inputs
ranking row 2582796 |
| 189 | = | Malignant Peritoneal Neoplasm | 53 | 85.3 | Medium confidence | clinicaltrials | inputs
ranking row 2582797 |
| 190 | = | Endometrial Carcinoma | 52 | 85.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582799 |
| 190 | = | Intrahepatic Cholangiocarcinoma | 52 | 85.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582798 |
| 190 | = | Pharyngeal Squamous Cell Carcinoma | 52 | 85.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582800 |
| 190 | = | Rectal Carcinoma | 52 | 85.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582801 |
| 194 | = | Chronic Myelomonocytic Leukemia | 51 | 84.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582802 |
| 194 | = | Malignant Infratentorial Neoplasm | 51 | 84.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582803 |
| 196 | = | Childhood Acute Leukemia | 50 | 84.7 | Medium confidence | clinicaltrials | inputs
ranking row 2582805 |
| 196 | = | Childhood Leukemia | 50 | 84.7 | Medium confidence | clinicaltrials | inputs
ranking row 2582804 |
| 196 | = | Myeloproliferative Neoplasm, BCR-ABL1 Negative | 50 | 84.7 | Medium confidence | clinicaltrials | inputs
ranking row 2582806 |
| 199 | = | Chronic Myeloid Leukemia, BCR-ABL1 Positive | 49 | 84.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582807 |
| 200 | = | Malignant Mixed Neoplasm | 48 | 84.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582808 |
| 201 | = | High-Grade Glioma, NOS | 47 | 84.3 | Medium confidence | clinicaltrials | inputs
ranking row 2582811 |
| 201 | = | Lung Non-Squamous Non-Small Cell Carcinoma | 47 | 84.3 | Medium confidence | clinicaltrials | inputs
ranking row 2582810 |
| 201 | = | Skin Squamous Cell Carcinoma | 47 | 84.3 | Medium confidence | clinicaltrials | inputs
ranking row 2582809 |
| 204 | = | Extrapulmonary Neuroendocrine Carcinoma | 46 | 84.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582812 |
| 204 | = | Oropharyngeal Squamous Cell Carcinoma | 46 | 84.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582813 |
| 206 | = | High Grade B-Cell Lymphoma | 45 | 83.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582814 |
| 207 | = | Esophageal Adenocarcinoma | 44 | 83.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582816 |
| 207 | = | Non-Cutaneous Melanoma | 44 | 83.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582815 |
| 207 | = | Peripheral T-Cell Lymphoma, Not Otherwise Specified | 44 | 83.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582817 |
| 210 | = | Glioblastoma, IDH-Wildtype | 43 | 83.6 | Medium confidence | clinicaltrials | inputs
ranking row 2582820 |
| 210 | = | Lip and Oral Cavity Carcinoma | 43 | 83.6 | Medium confidence | clinicaltrials | inputs
ranking row 2582821 |
| 210 | = | Malignant Brain Glioma | 43 | 83.6 | Medium confidence | clinicaltrials | inputs
ranking row 2582822 |
| 210 | = | Malignant Eye Neoplasm | 43 | 83.6 | Medium confidence | clinicaltrials | inputs
ranking row 2582818 |
| 210 | = | Malignant Thymus Neoplasm | 43 | 83.6 | Medium confidence | clinicaltrials | inputs
ranking row 2582819 |
| 210 | = | Oral Cavity Carcinoma | 43 | 83.6 | Medium confidence | clinicaltrials | inputs
ranking row 2582823 |
| 216 | = | Carcinomatosis | 42 | 83.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582825 |
| 216 | = | Cervical Non-Squamous Cell Carcinoma | 42 | 83.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582827 |
| 216 | = | Childhood Acute Lymphoblastic Leukemia | 42 | 83.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582826 |
| 216 | = | Secondary Carcinoma | 42 | 83.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582824 |
| 220 | = | Cervical Adenocarcinoma | 41 | 82.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582829 |
| 220 | = | Ewing Sarcoma | 41 | 82.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582828 |
| 220 | = | Invasive Breast Carcinoma | 41 | 82.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582830 |
| 220 | = | Malignant Laryngeal Neoplasm | 41 | 82.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582831 |
| 224 | = | Malignant Soft Tissue Neoplasm of Uncertain Differentiation | 40 | 82.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582832 |
| 225 | = | Adult Acute Myeloid Leukemia | 39 | 82.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582834 |
| 225 | = | Cutaneous Melanoma | 39 | 82.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582833 |
| 225 | = | Thyroid Gland Carcinoma | 39 | 82.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582835 |
| 228 | = | Acute Leukemia of Ambiguous Lineage | 38 | 82.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582837 |
| 228 | = | Ovarian Adenocarcinoma | 38 | 82.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582839 |
| 228 | = | Primary Central Nervous System Lymphoma | 38 | 82.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582838 |
| 228 | = | Virus-Related Carcinoma | 38 | 82.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582836 |
| 232 | = | Human Papillomavirus-Related Malignant Neoplasm | 37 | 81.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582841 |
| 232 | = | Lip and Oral Cavity Squamous Cell Carcinoma | 37 | 81.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582843 |
| 232 | = | Malignant Mediastinal Neoplasm | 37 | 81.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582840 |
| 232 | = | Oral Cavity Squamous Cell Carcinoma | 37 | 81.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582844 |
| 232 | = | Rhabdomyosarcoma | 37 | 81.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582842 |
| 237 | = | Human Papillomavirus-Related Carcinoma | 36 | 81.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582846 |
| 237 | = | Mediastinal Lymphoma | 36 | 81.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582847 |
| 237 | = | Primary Myelofibrosis | 36 | 81.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582848 |
| 237 | = | T Lymphoblastic Leukemia/Lymphoma | 36 | 81.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582845 |
| 241 | = | Carcinoma In Situ | 35 | 81.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582849 |
| 241 | = | Lymphoblastic Lymphoma | 35 | 81.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582850 |
| 241 | = | Non-Muscle Invasive Bladder Carcinoma | 35 | 81.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582853 |
| 241 | = | Primary Peritoneal Carcinoma | 35 | 81.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582851 |
| 241 | = | Serous Adenocarcinoma | 35 | 81.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582852 |
| 246 | = | Central Nervous System Embryonal Tumor | 34 | 80.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582854 |
| 246 | = | Malignant Anal Neoplasm | 34 | 80.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582855 |
| 248 | = | Early Stage Breast Carcinoma | 33 | 80.6 | Medium confidence | clinicaltrials | inputs
ranking row 2582856 |
| 248 | = | Lymphoplasmacytic Lymphoma | 33 | 80.6 | Medium confidence | clinicaltrials | inputs
ranking row 2582860 |
| 248 | = | Mediastinal Non-Hodgkin Lymphoma | 33 | 80.6 | Medium confidence | clinicaltrials | inputs
ranking row 2582857 |
| 248 | = | Primary Mediastinal Large B-Cell Lymphoma | 33 | 80.6 | Medium confidence | clinicaltrials | inputs
ranking row 2582859 |
| 248 | = | Thymus Lymphoma | 33 | 80.6 | Medium confidence | clinicaltrials | inputs
ranking row 2582858 |
| 253 | = | Aggressive T-Cell Non-Hodgkin Lymphoma | 32 | 80.3 | Medium confidence | clinicaltrials | inputs
ranking row 2582867 |
| 253 | = | Basal Cell Carcinoma | 32 | 80.3 | Medium confidence | clinicaltrials | inputs
ranking row 2582861 |
| 253 | = | Breast Ductal Carcinoma | 32 | 80.3 | Medium confidence | clinicaltrials | inputs
ranking row 2582868 |
| 253 | = | Cutaneous Lymphoma | 32 | 80.3 | Medium confidence | clinicaltrials | inputs
ranking row 2582862 |
| 253 | = | Diffuse Midline Glioma | 32 | 80.3 | Medium confidence | clinicaltrials | inputs
ranking row 2582869 |
| 253 | = | Malignant Salivary Gland Neoplasm | 32 | 80.3 | Medium confidence | clinicaltrials | inputs
ranking row 2582863 |
| 253 | = | Malignant Vulvar Neoplasm | 32 | 80.3 | Medium confidence | clinicaltrials | inputs
ranking row 2582870 |
| 253 | = | Ocular Melanoma | 32 | 80.3 | Medium confidence | clinicaltrials | inputs
ranking row 2582864 |
| 253 | = | Primary Cutaneous Lymphoma | 32 | 80.3 | Medium confidence | clinicaltrials | inputs
ranking row 2582865 |
| 253 | = | Primary Cutaneous Non-Hodgkin Lymphoma | 32 | 80.3 | Medium confidence | clinicaltrials | inputs
ranking row 2582866 |
| 253 | = | WHO Grade 3 Glioma | 32 | 80.3 | Medium confidence | clinicaltrials | inputs
ranking row 2582871 |
| 264 | = | Adenocarcinoma In Situ | 31 | 79.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582873 |
| 264 | = | Intraductal Carcinoma | 31 | 79.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582872 |
| 264 | = | Laryngeal Carcinoma | 31 | 79.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582875 |
| 264 | = | Malignant Cerebellar Neoplasm | 31 | 79.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582878 |
| 264 | = | Malignant Hypopharyngeal Neoplasm | 31 | 79.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582876 |
| 264 | = | Malignant Small Intestinal Neoplasm | 31 | 79.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582874 |
| 264 | = | Small Intestinal Carcinoma | 31 | 79.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582877 |
| 271 | = | Breast Carcinoma In Situ | 30 | 78.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582881 |
| 271 | = | Medulloblastoma | 30 | 78.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582879 |
| 271 | = | Platinum-Resistant Malignant Female Reproductive System Neoplasm | 30 | 78.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582882 |
| 271 | = | Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | 30 | 78.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582880 |
| 275 | = | Fallopian Tube Carcinoma | 29 | 78.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582887 |
| 275 | = | Malignant Ovarian Serous Tumor | 29 | 78.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582885 |
| 275 | = | Malignant Uveal Neoplasm | 29 | 78.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582883 |
| 275 | = | Mixed Phenotype Acute Leukemia | 29 | 78.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582888 |
| 275 | = | Ovarian Serous Adenocarcinoma | 29 | 78.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582889 |
| 275 | = | Platinum-Resistant Ovarian Carcinoma | 29 | 78.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582890 |
| 275 | = | T Acute Lymphoblastic Leukemia | 29 | 78.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582886 |
| 275 | = | Uveal Melanoma | 29 | 78.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582884 |
| 283 | = | Hypopharyngeal Carcinoma | 28 | 77.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582893 |
| 283 | = | Non-Small Cell Adenocarcinoma | 28 | 77.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582891 |
| 283 | = | Peritoneal Carcinomatosis | 28 | 77.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582892 |
| 283 | = | Rectal Adenocarcinoma | 28 | 77.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582894 |
| 287 | = | Breast Ductal Carcinoma In Situ | 27 | 77.6 | Medium confidence | clinicaltrials | inputs
ranking row 2582895 |
| 287 | = | Burkitt Lymphoma | 27 | 77.6 | Medium confidence | clinicaltrials | inputs
ranking row 2582897 |
| 287 | = | Lung Adenocarcinoma | 27 | 77.6 | Medium confidence | clinicaltrials | inputs
ranking row 2582898 |
| 287 | = | Renal Pelvis and Ureter Carcinoma | 27 | 77.6 | Medium confidence | clinicaltrials | inputs
ranking row 2582896 |
| 291 | = | Malignant Brain Stem Neoplasm | 26 | 77.3 | Medium confidence | clinicaltrials | inputs
ranking row 2582900 |
| 291 | = | Malignant Testicular Neoplasm | 26 | 77.3 | Medium confidence | clinicaltrials | inputs
ranking row 2582899 |
| 291 | = | Waldenstrom Macroglobulinemia | 26 | 77.3 | Medium confidence | clinicaltrials | inputs
ranking row 2582901 |
| 294 | = | Diffuse Intrinsic Pontine Glioma | 25 | 77 | Medium confidence | clinicaltrials | inputs
ranking row 2582908 |
| 294 | = | Erythroid Neoplasm | 25 | 77 | Medium confidence | clinicaltrials | inputs
ranking row 2582902 |
| 294 | = | Hormone Receptor-Positive Breast Carcinoma | 25 | 77 | Medium confidence | clinicaltrials | inputs
ranking row 2582909 |
| 294 | = | Laryngeal Squamous Cell Carcinoma | 25 | 77 | Medium confidence | clinicaltrials | inputs
ranking row 2582910 |
| 294 | = | Leiomyosarcoma | 25 | 77 | Medium confidence | clinicaltrials | inputs
ranking row 2582904 |
| 294 | = | Liposarcoma | 25 | 77 | Medium confidence | clinicaltrials | inputs
ranking row 2582903 |
| 294 | = | Merkel Cell Carcinoma | 25 | 77 | Medium confidence | clinicaltrials | inputs
ranking row 2582911 |
| 294 | = | Polycythemia Vera | 25 | 77 | Medium confidence | clinicaltrials | inputs
ranking row 2582905 |
| 294 | = | Salivary Gland Carcinoma | 25 | 77 | Medium confidence | clinicaltrials | inputs
ranking row 2582906 |
| 294 | = | Transformed Non-Hodgkin Lymphoma | 25 | 77 | Medium confidence | clinicaltrials | inputs
ranking row 2582907 |
| 304 | = | Colon Carcinoma | 24 | 76.3 | Medium confidence | clinicaltrials | inputs
ranking row 2582913 |
| 304 | = | Endometrioid Adenocarcinoma | 24 | 76.3 | Medium confidence | clinicaltrials | inputs
ranking row 2582912 |
| 306 | = | Bladder Urothelial Carcinoma | 23 | 76.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582917 |
| 306 | = | Human Papillomavirus-Related Squamous Cell Carcinoma | 23 | 76.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582916 |
| 306 | = | Malignant Cardiovascular Neoplasm | 23 | 76.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582914 |
| 306 | = | Malignant Retroperitoneal Neoplasm | 23 | 76.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582915 |
| 310 | = | Anaplastic Astrocytoma | 22 | 75.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582919 |
| 310 | = | Malignant Blood Vessel Neoplasm | 22 | 75.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582921 |
| 310 | = | Malignant Germ Cell Tumor | 22 | 75.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582918 |
| 310 | = | Malignant Penile Neoplasm | 22 | 75.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582924 |
| 310 | = | Malignant Vascular Neoplasm | 22 | 75.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582920 |
| 310 | = | Muscle Invasive Bladder Carcinoma | 22 | 75.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582925 |
| 310 | = | Synovial Sarcoma | 22 | 75.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582922 |
| 310 | = | Uterine Corpus Sarcoma | 22 | 75.8 | Medium confidence | clinicaltrials | inputs
ranking row 2582923 |
| 318 | = | Adult Acute Lymphoblastic Leukemia | 21 | 75.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582930 |
| 318 | = | Grade 3 Follicular Lymphoma | 21 | 75.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582931 |
| 318 | = | HER2-Negative Breast Carcinoma | 21 | 75.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582932 |
| 318 | = | Hypopharyngeal Squamous Cell Carcinoma | 21 | 75.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582934 |
| 318 | = | Large Cell Carcinoma | 21 | 75.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582928 |
| 318 | = | Malignant Histiocytic and Dendritic Cell Neoplasm | 21 | 75.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582926 |
| 318 | = | Secondary Acute Myeloid Leukemia | 21 | 75.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582929 |
| 318 | = | Small Intestinal Adenocarcinoma | 21 | 75.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582933 |
| 318 | = | Tobacco-Related Carcinoma | 21 | 75.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582927 |
| 327 | = | Female Reproductive System Endometrioid Adenocarcinoma | 20 | 74.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582936 |
| 327 | = | Malignant Vaginal Neoplasm | 20 | 74.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582937 |
| 327 | = | Papillary Carcinoma | 20 | 74.5 | Medium confidence | clinicaltrials | inputs
ranking row 2582935 |
| 330 | = | Acute Myeloid Leukemia with Genetic Abnormalities | 19 | 74.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582945 |
| 330 | = | Extrahepatic Cholangiocarcinoma | 19 | 74.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582947 |
| 330 | = | Head and Neck Adenocarcinoma | 19 | 74.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582941 |
| 330 | = | Lung Squamous Cell Carcinoma | 19 | 74.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582942 |
| 330 | = | Malignant Appendix Neoplasm | 19 | 74.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582939 |
| 330 | = | Malignant Extrahepatic Bile Duct Neoplasm | 19 | 74.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582946 |
| 330 | = | Malignant Meningeal Neoplasm | 19 | 74.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582943 |
| 330 | = | Papillary Adenocarcinoma | 19 | 74.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582944 |
| 330 | = | Rare Childhood Malignant Neoplasm | 19 | 74.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582938 |
| 330 | = | Virus-Related Lymphoma | 19 | 74.2 | Medium confidence | clinicaltrials | inputs
ranking row 2582940 |
| 340 | = | Anal Carcinoma | 18 | 73.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582951 |
| 340 | = | Childhood Carcinoma | 18 | 73.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582948 |
| 340 | = | Childhood Malignant Nervous System Neoplasm | 18 | 73.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582949 |
| 340 | = | Endometrial Adenocarcinoma | 18 | 73.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582952 |
| 340 | = | Malignant Sinonasal Neoplasm | 18 | 73.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582950 |
| 340 | = | Malignant Supratentorial Neoplasm | 18 | 73.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582953 |
| 340 | = | Pediatric-Type Diffuse High-Grade Glioma | 18 | 73.4 | Medium confidence | clinicaltrials | inputs
ranking row 2582954 |
| 347 | = | Adenoid Cystic Carcinoma | 17 | 72.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582956 |
| 347 | = | Adult Lymphoma | 17 | 72.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582957 |
| 347 | = | Childhood Malignant Central Nervous System Neoplasm | 17 | 72.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582960 |
| 347 | = | Childhood Malignant Digestive System Neoplasm | 17 | 72.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582958 |
| 347 | = | Classic Hodgkin Lymphoma | 17 | 72.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582961 |
| 347 | = | Extranodal Lymphoma | 17 | 72.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582962 |
| 347 | = | Extranodal Non-Hodgkin Lymphoma | 17 | 72.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582963 |
| 347 | = | Head and Neck Carcinoma, Other | 17 | 72.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582966 |
| 347 | = | High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements | 17 | 72.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582965 |
| 347 | = | Malignant Bone Neoplasm | 17 | 72.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582959 |
| 347 | = | Thyroid Gland Adenocarcinoma | 17 | 72.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582964 |
| 347 | = | Wilms Tumor | 17 | 72.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582955 |
| 359 | = | Adrenal Cortical Carcinoma | 16 | 71.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582969 |
| 359 | = | Human Papillomavirus-Related Head and Neck Mucosal Squamous Cell Carcinoma | 16 | 71.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582972 |
| 359 | = | Human Papillomavirus-Related Oropharyngeal Squamous Cell Carcinoma | 16 | 71.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582977 |
| 359 | = | Human Papillomavirus-Related Pharyngeal Squamous Cell Carcinoma | 16 | 71.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582975 |
| 359 | = | Indolent T-Cell Non-Hodgkin Lymphoma | 16 | 71.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582976 |
| 359 | = | Malignant Adrenal Cortical Neoplasm | 16 | 71.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582973 |
| 359 | = | Malignant Adrenal Gland Neoplasm | 16 | 71.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582970 |
| 359 | = | Plasma Cell Leukemia | 16 | 71.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582967 |
| 359 | = | Renal Pelvis and Ureter Urothelial Carcinoma | 16 | 71.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582974 |
| 359 | = | Retroperitoneal Carcinoma | 16 | 71.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582968 |
| 359 | = | Sinonasal Carcinoma | 16 | 71.9 | Medium confidence | clinicaltrials | inputs
ranking row 2582971 |
| 370 | = | Breast Lobular Carcinoma | 15 | 71.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582982 |
| 370 | = | Colon Adenocarcinoma | 15 | 71.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582986 |
| 370 | = | Differentiated Thyroid Gland Carcinoma | 15 | 71.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582983 |
| 370 | = | Diffuse Midline Glioma, H3 K27-Altered | 15 | 71.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582987 |
| 370 | = | Essential Thrombocythemia | 15 | 71.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582980 |
| 370 | = | Invasive Bladder Urothelial Carcinoma | 15 | 71.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582984 |
| 370 | = | Invasive Urothelial Carcinoma | 15 | 71.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582981 |
| 370 | = | Megakaryocytic Neoplasm | 15 | 71.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582978 |
| 370 | = | Mycosis Fungoides | 15 | 71.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582985 |
| 370 | = | Mycosis Fungoides and Sezary Syndrome | 15 | 71.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582988 |
| 370 | = | Renal Non-Clear Cell Carcinoma | 15 | 71.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582989 |
| 370 | = | Undifferentiated Carcinoma | 15 | 71.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582979 |
| 382 | = | Anaplastic Large Cell Lymphoma | 14 | 70.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582991 |
| 382 | = | Bone Sarcoma | 14 | 70.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582992 |
| 382 | = | Childhood Malignant Brain Neoplasm | 14 | 70.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582994 |
| 382 | = | Hereditary Malignant Neoplasm | 14 | 70.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582990 |
| 382 | = | Malignant Gallbladder Neoplasm | 14 | 70.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582993 |
| 382 | = | Non-Clear Cell Renal Cell Carcinoma | 14 | 70.1 | Medium confidence | clinicaltrials | inputs
ranking row 2582995 |
| 388 | = | Adenosquamous Carcinoma | 13 | 69.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583002 |
| 388 | = | Adult Glioblastoma | 13 | 69.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583003 |
| 388 | = | Adult Non-Hodgkin Lymphoma | 13 | 69.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583004 |
| 388 | = | Ampulla of Vater Carcinoma | 13 | 69.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583024 |
| 388 | = | Anal Squamous Cell Carcinoma | 13 | 69.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583005 |
| 388 | = | Carcinosarcoma | 13 | 69.7 | Medium confidence | clinicaltrials | inputs
ranking row 2582997 |
| 388 | = | Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive | 13 | 69.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583006 |
| 388 | = | Diffuse Midline Glioma, H3 K27M-Mutant | 13 | 69.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583027 |
| 388 | = | Duodenal Carcinoma | 13 | 69.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583025 |
| 388 | = | Female Reproductive System Squamous Cell Carcinoma | 13 | 69.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583007 |
| 388 | = | Gliosarcoma | 13 | 69.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583016 |
| 388 | = | Head and Neck Cutaneous Carcinoma | 13 | 69.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583008 |
| 388 | = | Head and Neck Cutaneous Squamous Cell Carcinoma | 13 | 69.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583017 |
| 388 | = | Head and Neck Undifferentiated Carcinoma | 13 | 69.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583009 |
| 388 | = | HHV8-Related Malignant Neoplasm | 13 | 69.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583010 |
| 388 | = | High Grade Serous Adenocarcinoma | 13 | 69.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583018 |
| 388 | = | Malignant Ampulla of Vater Neoplasm | 13 | 69.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583019 |
| 388 | = | Malignant Duodenal Neoplasm | 13 | 69.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583020 |
| 388 | = | Malignant Ovarian Endometrioid Tumor | 13 | 69.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583011 |
| 388 | = | Malignant Peripheral Nerve Sheath Tumor | 13 | 69.7 | Medium confidence | clinicaltrials | inputs
ranking row 2582998 |
| 388 | = | Malignant Peripheral Nervous System Neoplasm | 13 | 69.7 | Medium confidence | clinicaltrials | inputs
ranking row 2582999 |
| 388 | = | Mixed Carcinoma | 13 | 69.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583000 |
| 388 | = | Mucosal Melanoma | 13 | 69.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583012 |
| 388 | = | Ovarian Endometrioid Adenocarcinoma | 13 | 69.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583021 |
| 388 | = | Ovarian High Grade Serous Adenocarcinoma | 13 | 69.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583026 |
| 388 | = | Small Cell Sarcoma | 13 | 69.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583001 |
| 388 | = | Smoldering Multiple Myeloma | 13 | 69.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583013 |
| 388 | = | Therapy-Related Malignant Neoplasm | 13 | 69.7 | Medium confidence | clinicaltrials | inputs
ranking row 2582996 |
| 388 | = | Thyroid Gland Papillary Carcinoma | 13 | 69.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583022 |
| 388 | = | Transformed B-Cell Non-Hodgkin Lymphoma | 13 | 69.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583014 |
| 388 | = | Undifferentiated Sarcoma | 13 | 69.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583015 |
| 388 | = | Vulvar Carcinoma | 13 | 69.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583023 |
| 420 | = | Brain Glioblastoma | 12 | 67.2 | Medium confidence | clinicaltrials | inputs
ranking row 2583033 |
| 420 | = | Childhood Central Nervous System Embryonal Tumor | 12 | 67.2 | Medium confidence | clinicaltrials | inputs
ranking row 2583028 |
| 420 | = | Childhood Medulloblastoma | 12 | 67.2 | Medium confidence | clinicaltrials | inputs
ranking row 2583034 |
| 420 | = | Duodenal Adenocarcinoma | 12 | 67.2 | Medium confidence | clinicaltrials | inputs
ranking row 2583039 |
| 420 | = | Grade 3b Follicular Lymphoma | 12 | 67.2 | Medium confidence | clinicaltrials | inputs
ranking row 2583040 |
| 420 | = | HER2-Low Breast Carcinoma | 12 | 67.2 | Medium confidence | clinicaltrials | inputs
ranking row 2583036 |
| 420 | = | Interdigitating Dendritic Cell Sarcoma | 12 | 67.2 | Medium confidence | clinicaltrials | inputs
ranking row 2583029 |
| 420 | = | Malignant Pleural Neoplasm | 12 | 67.2 | Medium confidence | clinicaltrials | inputs
ranking row 2583030 |
| 420 | = | Meningeal Carcinomatosis | 12 | 67.2 | Medium confidence | clinicaltrials | inputs
ranking row 2583037 |
| 420 | = | Myelodysplastic Syndrome with Excess Blasts | 12 | 67.2 | Medium confidence | clinicaltrials | inputs
ranking row 2583035 |
| 420 | = | Penile Carcinoma | 12 | 67.2 | Medium confidence | clinicaltrials | inputs
ranking row 2583038 |
| 420 | = | Pleural Malignant Mesothelioma | 12 | 67.2 | Medium confidence | clinicaltrials | inputs
ranking row 2583031 |
| 420 | = | Solid Carcinoma | 12 | 67.2 | Medium confidence | clinicaltrials | inputs
ranking row 2583032 |
| 433 | = | Aggressive Adult Non-Hodgkin Lymphoma | 11 | 66.1 | Medium confidence | clinicaltrials | inputs
ranking row 2583047 |
| 433 | = | Desmoplastic Small Round Cell Tumor | 11 | 66.1 | Medium confidence | clinicaltrials | inputs
ranking row 2583043 |
| 433 | = | Female Reproductive System Clear Cell Adenocarcinoma | 11 | 66.1 | Medium confidence | clinicaltrials | inputs
ranking row 2583048 |
| 433 | = | Fibrosarcoma | 11 | 66.1 | Medium confidence | clinicaltrials | inputs
ranking row 2583042 |
| 433 | = | Hepatoblastoma | 11 | 66.1 | Medium confidence | clinicaltrials | inputs
ranking row 2583041 |
| 433 | = | High Grade B-Cell Lymphoma with MYC and BCL2 or BCL6 Rearrangements | 11 | 66.1 | Medium confidence | clinicaltrials | inputs
ranking row 2583051 |
| 433 | = | Kaposi Sarcoma | 11 | 66.1 | Medium confidence | clinicaltrials | inputs
ranking row 2583049 |
| 433 | = | Prolymphocytic Leukemia | 11 | 66.1 | Medium confidence | clinicaltrials | inputs
ranking row 2583044 |
| 433 | = | Skin Basal Cell Carcinoma | 11 | 66.1 | Medium confidence | clinicaltrials | inputs
ranking row 2583045 |
| 433 | = | Undifferentiated Pleomorphic Sarcoma | 11 | 66.1 | Medium confidence | clinicaltrials | inputs
ranking row 2583050 |
| 433 | = | Virus-Related Sarcoma | 11 | 66.1 | Medium confidence | clinicaltrials | inputs
ranking row 2583046 |
| 444 | = | Angiosarcoma | 10 | 65.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583057 |
| 444 | = | Childhood Acute Myeloid Leukemia | 10 | 65.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583058 |
| 444 | = | Childhood Gastric Carcinoma | 10 | 65.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583055 |
| 444 | = | Chondrosarcoma | 10 | 65.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583052 |
| 444 | = | Female Reproductive System Carcinosarcoma | 10 | 65.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583056 |
| 444 | = | Follicular Helper T-Cell Lymphoma | 10 | 65.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583059 |
| 444 | = | Head and Neck Neuroendocrine Carcinoma | 10 | 65.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583053 |
| 444 | = | Thymus Carcinoma | 10 | 65.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583054 |
| 452 | = | Accelerated Phase Myeloproliferative Neoplasm | 9 | 64.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583074 |
| 452 | = | Acral Melanoma | 9 | 64.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583075 |
| 452 | = | Alveolar Soft Part Sarcoma | 9 | 64.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583066 |
| 452 | = | Appendix Carcinoma | 9 | 64.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583067 |
| 452 | = | Astrocytoma, IDH-Mutant, Grade 4 | 9 | 64.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583060 |
| 452 | = | B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | 9 | 64.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583076 |
| 452 | = | Blastic Plasmacytoid Dendritic Cell Neoplasm | 9 | 64.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583068 |
| 452 | = | Blast Phase Myeloproliferative Neoplasm | 9 | 64.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583077 |
| 452 | = | B-Lymphoblastic Leukemia/Lymphoma with Recurrent Genetic Abnormalities | 9 | 64.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583089 |
| 452 | = | Cigarette Smoking-Related Carcinoma | 9 | 64.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583061 |
| 452 | = | Classic Follicular Lymphoma | 9 | 64.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583080 |
| 452 | = | Cutaneous Melanoma of the Extremity | 9 | 64.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583069 |
| 452 | = | Dedifferentiated Liposarcoma | 9 | 64.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583070 |
| 452 | = | Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type | 9 | 64.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583081 |
| 452 | = | Germinomatous Germ Cell Tumor | 9 | 64.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583062 |
| 452 | = | Hairy Cell Leukemia | 9 | 64.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583063 |
| 452 | = | High Grade Endometrial Carcinoma | 9 | 64.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583082 |
| 452 | = | Hilar Cholangiocarcinoma | 9 | 64.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583086 |
| 452 | = | Juvenile Myelomonocytic Leukemia | 9 | 64.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583064 |
| 452 | = | Large Cell Neuroendocrine Carcinoma | 9 | 64.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583071 |
| 452 | = | Lung Non-Small Cell Squamous Carcinoma | 9 | 64.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583078 |
| 452 | = | Malignant Cerebral Neoplasm | 9 | 64.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583087 |
| 452 | = | Microsatellite Stable Colorectal Carcinoma | 9 | 64.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583083 |
| 452 | = | Mucinous Adenocarcinoma | 9 | 64.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583072 |
| 452 | = | Nasal Type Extranodal NK/T-Cell Lymphoma | 9 | 64.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583079 |
| 452 | = | Plasmacytoid Dendritic Cell Neoplasm | 9 | 64.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583065 |
| 452 | = | Primary Brain Tumor | 9 | 64.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583088 |
| 452 | = | Sporadic Gastric Adenocarcinoma | 9 | 64.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583084 |
| 452 | = | Thyroid Gland Anaplastic Carcinoma | 9 | 64.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583073 |
| 452 | = | Type II Endometrial Adenocarcinoma | 9 | 64.7 | Medium confidence | clinicaltrials | inputs
ranking row 2583085 |
| 482 | = | Acute Promyelocytic Leukemia | 8 | 62.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583116 |
| 482 | = | Adult T-Cell Leukemia/Lymphoma | 8 | 62.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583093 |
| 482 | = | B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 | 8 | 62.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583112 |
| 482 | = | B Lymphoblastic Leukemia/Lymphoma with t(9;22)(q34.1;q11.2); BCR-ABL1 | 8 | 62.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583101 |
| 482 | = | Cervical Squamous Cell Carcinoma | 8 | 62.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583094 |
| 482 | = | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | 8 | 62.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583113 |
| 482 | = | Early Gastric Carcinoma | 8 | 62.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583117 |
| 482 | = | EBV-Related Malignant Neoplasm | 8 | 62.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583095 |
| 482 | = | Endometrial Endometrioid Adenocarcinoma | 8 | 62.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583102 |
| 482 | = | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | 8 | 62.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583103 |
| 482 | = | Fallopian Tube Adenocarcinoma | 8 | 62.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583104 |
| 482 | = | Fibrolamellar Carcinoma | 8 | 62.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583105 |
| 482 | = | Gallbladder Carcinoma | 8 | 62.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583106 |
| 482 | = | Grade 3a Follicular Lymphoma | 8 | 62.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583114 |
| 482 | = | High-Grade Serous Ovarian Cancer | 8 | 62.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583121 |
| 482 | = | HTLV-1-Related Malignant Neoplasm | 8 | 62.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583096 |
| 482 | = | Human Papillomavirus-Related Cervical Carcinoma | 8 | 62.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583107 |
| 482 | = | Malignant Pineal Region Neoplasm | 8 | 62.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583118 |
| 482 | = | Malignant Retinal Neoplasm | 8 | 62.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583090 |
| 482 | = | Malignant Tongue Neoplasm | 8 | 62.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583108 |
| 482 | = | Oligometastatic Malignant Neoplasm | 8 | 62.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583091 |
| 482 | = | Ovarian Carcinosarcoma | 8 | 62.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583109 |
| 482 | = | Pediatric-Type Diffuse Low-Grade Glioma | 8 | 62.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583120 |
| 482 | = | Periampullary Adenocarcinoma | 8 | 62.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583119 |
| 482 | = | Retinoblastoma | 8 | 62.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583097 |
| 482 | = | Sarcomatoid Carcinoma | 8 | 62.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583092 |
| 482 | = | Seminoma | 8 | 62.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583098 |
| 482 | = | Sinonasal Squamous Cell Carcinoma | 8 | 62.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583110 |
| 482 | = | Soft Tissue Sarcoma of the Trunk and Extremities | 8 | 62.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583099 |
| 482 | = | Thyroid Gland Medullary Carcinoma | 8 | 62.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583100 |
| 482 | = | Type I Endometrial Adenocarcinoma | 8 | 62.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583115 |
| 482 | = | Vaginal Carcinoma | 8 | 62.3 | Medium confidence | clinicaltrials | inputs
ranking row 2583111 |
| 514 | = | Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive | 7 | 59.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583136 |
| 514 | = | Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive | 7 | 59.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583137 |
| 514 | = | Childhood Colorectal Carcinoma | 7 | 59.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583125 |
| 514 | = | Childhood Malignant Intestinal Neoplasm | 7 | 59.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583126 |
| 514 | = | EBV-Related Lymphoma | 7 | 59.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583127 |
| 514 | = | Endometrial Serous Adenocarcinoma | 7 | 59.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583138 |
| 514 | = | Extramammary Paget Disease | 7 | 59.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583139 |
| 514 | = | Extrapulmonary Small Cell Neuroendocrine Carcinoma | 7 | 59.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583140 |
| 514 | = | Germ Cell Tumor, Brain | 7 | 59.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583152 |
| 514 | = | Grade 1 Follicular Lymphoma | 7 | 59.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583150 |
| 514 | = | Grade 2 Follicular Lymphoma | 7 | 59.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583151 |
| 514 | = | Grade 3 Meningioma | 7 | 59.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583128 |
| 514 | = | High Risk Neuroblastoma | 7 | 59.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583141 |
| 514 | = | Malignant Ovarian Clear Cell Tumor | 7 | 59.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583129 |
| 514 | = | Malignant Splenic Neoplasm | 7 | 59.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583122 |
| 514 | = | Malignant Urethral Neoplasm | 7 | 59.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583142 |
| 514 | = | MGMT-Unmethylated Glioblastoma | 7 | 59.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583143 |
| 514 | = | Myeloid Neoplasm Post Cytotoxic Therapy | 7 | 59.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583123 |
| 514 | = | Oligometastatic Carcinoma | 7 | 59.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583130 |
| 514 | = | Ovarian Clear Cell Adenocarcinoma | 7 | 59.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583144 |
| 514 | = | Paget Disease | 7 | 59.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583131 |
| 514 | = | Penile Squamous Cell Carcinoma | 7 | 59.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583132 |
| 514 | = | Platinum-Sensitive Malignant Female Reproductive System Neoplasm | 7 | 59.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583145 |
| 514 | = | Platinum-Sensitive Ovarian Carcinoma | 7 | 59.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583146 |
| 514 | = | Primary Peritoneal Adenocarcinoma | 7 | 59.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583133 |
| 514 | = | Primary Peritoneal Serous Adenocarcinoma | 7 | 59.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583147 |
| 514 | = | Retroperitoneal Sarcoma | 7 | 59.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583134 |
| 514 | = | Secondary Central Nervous System Lymphoma | 7 | 59.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583135 |
| 514 | = | T-Cell Prolymphocytic Leukemia | 7 | 59.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583148 |
| 514 | = | Therapy-Related Leukemia | 7 | 59.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583124 |
| 514 | = | Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma | 7 | 59.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583149 |
| 545 | = | Acute Biphenotypic Leukemia | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583180 |
| 545 | = | Acute Monoblastic and Monocytic Leukemia | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583181 |
| 545 | = | Acute Monocytic Leukemia | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583188 |
| 545 | = | Acute Myeloid Leukemia Arising from Previous Myelodysplastic Syndrome | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583160 |
| 545 | = | Acute Myeloid Leukemia, Not Otherwise Specified | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583175 |
| 545 | = | Acute Myeloid Leukemia Post Cytotoxic Therapy | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583161 |
| 545 | = | AML with Recurrent Genetic Abnormalities | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583190 |
| 545 | = | Anaplastic Oligodendroglioma | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583154 |
| 545 | = | Atypical Teratoid/Rhabdoid Tumor | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583155 |
| 545 | = | Childhood Lymphoma | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583156 |
| 545 | = | Clear Cell Sarcoma of Soft Tissue | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583162 |
| 545 | = | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified by Gene Expression Profile | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583189 |
| 545 | = | Diffuse Large B-Cell Lymphoma Unclassifiable | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583176 |
| 545 | = | Early Stage Bladder Urothelial Carcinoma | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583182 |
| 545 | = | EBV-Related Non-Hodgkin Lymphoma | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583163 |
| 545 | = | Embryonal Tumor with Multilayered Rosettes | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583157 |
| 545 | = | Estrogen Receptor-Positive Breast Carcinoma | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583183 |
| 545 | = | Fallopian Tube Serous Adenocarcinoma | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583177 |
| 545 | = | Ganglioneuroblastoma | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583164 |
| 545 | = | Head and Neck Carcinoma of Unknown Primary | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583165 |
| 545 | = | HER2-Positive Gastric Adenocarcinoma | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583184 |
| 545 | = | Leukemic Phase of Non-Hodgkin Lymphoma | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583166 |
| 545 | = | Malignant Abdominal Neoplasm | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583153 |
| 545 | = | Muscle Invasive Bladder Urothelial Carcinoma | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583185 |
| 545 | = | Myelodysplastic Syndrome/Acute Myeloid Leukemia | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583167 |
| 545 | = | Myxofibrosarcoma | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583178 |
| 545 | = | Myxoid Liposarcoma | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583168 |
| 545 | = | Non-Muscle Invasive Bladder Urothelial Carcinoma | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583186 |
| 545 | = | Olfactory Neuroblastoma | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583169 |
| 545 | = | Pineoblastoma | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583158 |
| 545 | = | Primary Peritoneal Endometrioid Adenocarcinoma | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583170 |
| 545 | = | Pseudomyxoma Peritonei | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583179 |
| 545 | = | Sarcomatoid Renal Cell Carcinoma | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583171 |
| 545 | = | Soft Tissue Fibrosarcoma | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583172 |
| 545 | = | Splenic Lymphoma | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583159 |
| 545 | = | Splenic Non-Hodgkin Lymphoma | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583173 |
| 545 | = | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583187 |
| 545 | = | Vulvar Squamous Cell Carcinoma | 6 | 57.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583174 |
| 583 | = | Acute Myeloid Leukemia, Myelodysplasia-Related | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583216 |
| 583 | = | Acute Undifferentiated Leukemia | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583217 |
| 583 | = | Adult Hodgkin Lymphoma | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583204 |
| 583 | = | ALK-Positive Lung Non-Small Cell Carcinoma | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583234 |
| 583 | = | Amyloidosis | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583240 |
| 583 | = | Astrocytoma, IDH-Mutant, Grade 3 | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583205 |
| 583 | = | Breast Lobular Carcinoma In Situ | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583194 |
| 583 | = | Childhood Non-Hodgkin Lymphoma | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583206 |
| 583 | = | Childhood Sarcoma | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583195 |
| 583 | = | Chordoma | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583191 |
| 583 | = | Diffuse Hemispheric Glioma, H3 G34-Mutant | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583218 |
| 583 | = | Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583239 |
| 583 | = | Digestive System Adenosquamous Carcinoma | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583207 |
| 583 | = | Digestive System Lymphoma | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583196 |
| 583 | = | Digestive System Non-Hodgkin Lymphoma | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583208 |
| 583 | = | Early Stage Triple-Negative Breast Carcinoma | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583219 |
| 583 | = | EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583220 |
| 583 | = | Epithelioid Sarcoma | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583209 |
| 583 | = | Fallopian Tube Endometrioid Adenocarcinoma | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583210 |
| 583 | = | Hereditary Breast Carcinoma | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583197 |
| 583 | = | Hormone Receptor-Negative Breast Carcinoma | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583221 |
| 583 | = | Human Papillomavirus-Related Anal Squamous Cell Carcinoma | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583222 |
| 583 | = | Immunodeficiency-Related Malignant Neoplasm | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583192 |
| 583 | = | Invasive Breast Lobular Carcinoma | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583223 |
| 583 | = | Low Grade Sarcoma | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583198 |
| 583 | = | Lung Large Cell Neuroendocrine Carcinoma | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583224 |
| 583 | = | Lung Non-Small Cell Carcinoma with Genetic Abnormalities | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583225 |
| 583 | = | Malignant Mixed Mesodermal (Mullerian) Tumor | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583199 |
| 583 | = | Malignant Paranasal Sinus Neoplasm | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583211 |
| 583 | = | Malignant Pelvic Neoplasm | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583193 |
| 583 | = | Malignant Renal Pelvis Neoplasm | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583226 |
| 583 | = | Malignant Skin Adnexal Neoplasm | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583200 |
| 583 | = | Malignant Testicular Germ Cell Tumor | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583201 |
| 583 | = | Malignant Ureter Neoplasm | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583227 |
| 583 | = | Malignant Uterine Corpus Mixed Epithelial and Mesenchymal Neoplasm | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583202 |
| 583 | = | MGMT-Methylated Glioblastoma | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583228 |
| 583 | = | Nodal Marginal Zone Lymphoma | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583238 |
| 583 | = | Pancreatic Adenosquamous Carcinoma | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583229 |
| 583 | = | Papillary Renal Cell Carcinoma | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583230 |
| 583 | = | Paranasal Sinus Carcinoma | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583231 |
| 583 | = | Pharyngeal Carcinoma by AJCC v8 Stage | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583235 |
| 583 | = | Plasmablastic Lymphoma | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583236 |
| 583 | = | Platinum-Resistant Fallopian Tube Carcinoma | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583237 |
| 583 | = | Platinum-Resistant Primary Peritoneal Carcinoma | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583212 |
| 583 | = | Pleomorphic Liposarcoma | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583213 |
| 583 | = | Sezary Syndrome | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583232 |
| 583 | = | T-Cell Large Granular Lymphocyte Leukemia | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583215 |
| 583 | = | T Lymphoblastic Lymphoma | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583214 |
| 583 | = | Uterine Carcinosarcoma | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583233 |
| 583 | = | Yolk Sac Tumor | 5 | 54.4 | Medium confidence | clinicaltrials | inputs
ranking row 2583203 |
| 633 | = | Acute Myeloid Leukemia with NPM1 Mutation | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583279 |
| 633 | = | Ampulla of Vater Adenocarcinoma | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583268 |
| 633 | = | Appendix Adenocarcinoma | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583258 |
| 633 | = | Atypical Chronic Myeloid Leukemia | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583248 |
| 633 | = | Biliary Tract Adenocarcinoma | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583259 |
| 633 | = | Bladder Non-Urothelial Carcinoma | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583280 |
| 633 | = | Bladder Squamous Cell Carcinoma | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583260 |
| 633 | = | B Lymphoblastic Lymphoma | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583249 |
| 633 | = | Breast Inflammatory Carcinoma | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583261 |
| 633 | = | Castration-Sensitive Prostate Carcinoma | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583269 |
| 633 | = | Cervical Adenosquamous Carcinoma | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583270 |
| 633 | = | Core Binding Factor Acute Myeloid Leukemia | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583281 |
| 633 | = | Distal Cholangiocarcinoma | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583282 |
| 633 | = | Endometrial Clear Cell Adenocarcinoma | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583271 |
| 633 | = | Epithelioid Hemangioendothelioma | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583250 |
| 633 | = | Fallopian Tube Clear Cell Adenocarcinoma | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583272 |
| 633 | = | Fallopian Tube High Grade Serous Adenocarcinoma | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583273 |
| 633 | = | Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583251 |
| 633 | = | Female Reproductive System Adenosquamous Carcinoma | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583262 |
| 633 | = | High Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583284 |
| 633 | = | Malignant Nasal Cavity Neoplasm | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583252 |
| 633 | = | Metaplastic Carcinoma | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583243 |
| 633 | = | Myeloid Sarcoma | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583241 |
| 633 | = | Nasopharyngeal Carcinoma by AJCC v8 Stage | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583283 |
| 633 | = | Nasopharyngeal Squamous Cell Carcinoma | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583274 |
| 633 | = | NUT Carcinoma | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583244 |
| 633 | = | Paranasal Sinus Squamous Cell Carcinoma | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583275 |
| 633 | = | Peritoneal Malignant Mesothelioma | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583245 |
| 633 | = | Primary Peritoneal Carcinosarcoma | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583253 |
| 633 | = | Primary Peritoneal Clear Cell Adenocarcinoma | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583263 |
| 633 | = | Primary Peritoneal High Grade Serous Adenocarcinoma | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583276 |
| 633 | = | Prostate Neuroendocrine Carcinoma | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583254 |
| 633 | = | Renal Pelvis Carcinoma | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583264 |
| 633 | = | Secondary Myelodysplastic Syndrome | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583246 |
| 633 | = | Sinonasal Undifferentiated Carcinoma | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583265 |
| 633 | = | Skin Adnexal Carcinoma | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583255 |
| 633 | = | Splenic Marginal Zone Lymphoma | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583266 |
| 633 | = | Squamous Cell Carcinoma of Unknown Primary | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583267 |
| 633 | = | Stromal Sarcoma | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583247 |
| 633 | = | Thyroid Gland Follicular Carcinoma | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583242 |
| 633 | = | Urethral Carcinoma | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583277 |
| 633 | = | Urinary Tract Non-Urothelial Carcinoma | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583278 |
| 633 | = | Urinary Tract Squamous Cell Carcinoma | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583256 |
| 633 | = | Uterine Corpus Carcinosarcoma | 4 | 50.5 | Medium confidence | clinicaltrials | inputs
ranking row 2583257 |
| 677 | = | Acinar Cell Carcinoma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583294 |
| 677 | = | Acute Myeloid Leukemia with FLT3/ITD Mutation | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583345 |
| 677 | = | Acute Myeloid Leukemia with FLT3 Mutation | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583339 |
| 677 | = | Acute Myeloid Leukemia with KMT2A Rearrangement | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583340 |
| 677 | = | Acute Myeloid Leukemia with Other Genetic Abnormalities | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583330 |
| 677 | = | Acute Promyelocytic Leukemia with t(15;17)(q24.1;q21.2); PML-RARA | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583346 |
| 677 | = | Adult B Acute Lymphoblastic Leukemia | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583313 |
| 677 | = | Adult Lymphoblastic Lymphoma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583295 |
| 677 | = | Aggressive NK-Cell Leukemia | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583296 |
| 677 | = | AIDS-Related Lymphoma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583297 |
| 677 | = | AIDS-Related Malignant Neoplasm | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583285 |
| 677 | = | Anaplastic Ependymoma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583286 |
| 677 | = | Anaplastic Large Cell Lymphoma, ALK-Positive | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583298 |
| 677 | = | BCLC Stage C Hepatocellular Carcinoma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583331 |
| 677 | = | Bladder Adenocarcinoma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583332 |
| 677 | = | Breast Metaplastic Carcinoma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583299 |
| 677 | = | Central Nervous System Carcinoma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583287 |
| 677 | = | Childhood B Acute Lymphoblastic Leukemia | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583300 |
| 677 | = | Childhood B Lymphoblastic Leukemia/Lymphoma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583288 |
| 677 | = | Childhood Lymphoblastic Lymphoma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583301 |
| 677 | = | Childhood Malignant Glioma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583314 |
| 677 | = | Childhood Malignant Solid Neoplasm | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583289 |
| 677 | = | Childhood Soft Tissue Sarcoma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583302 |
| 677 | = | Chromophobe Renal Cell Carcinoma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583341 |
| 677 | = | Chronic Myelomonocytic Leukemia-2 | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583315 |
| 677 | = | Collecting Duct Carcinoma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583333 |
| 677 | = | Diffuse Large B-Cell Lymphoma Activated B-Cell Type | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583316 |
| 677 | = | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified Molecular Subtypes | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583342 |
| 677 | = | Digestive System Neuroendocrine Carcinoma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583290 |
| 677 | = | Double-Expressor Lymphoma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583334 |
| 677 | = | Endometrial Mixed Cell Adenocarcinoma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583335 |
| 677 | = | Endometrioid Stromal Sarcoma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583303 |
| 677 | = | Enteropathy-Associated T-Cell Lymphoma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583343 |
| 677 | = | Hepatocellular Carcinoma by BCLC Stage | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583317 |
| 677 | = | Hereditary Malignant Urinary System Neoplasm | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583291 |
| 677 | = | Hereditary Renal Cell Carcinoma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583304 |
| 677 | = | High Grade Follicular Cell-Derived Non-Anaplastic Thyroid Gland Carcinoma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583318 |
| 677 | = | Intestinal Lymphoma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583305 |
| 677 | = | Intestinal Non-Hodgkin Lymphoma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583319 |
| 677 | = | Intestinal T-Cell Lymphoma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583336 |
| 677 | = | Invasive Breast Carcinoma of No Special Type | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583320 |
| 677 | = | Kidney Wilms Tumor | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583292 |
| 677 | = | Low-Grade Serous Ovarian Cancer | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583350 |
| 677 | = | Lymphoepithelial Carcinoma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583306 |
| 677 | = | Malignant Anal Canal Neoplasm | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583344 |
| 677 | = | Malignant Extragonadal Germ Cell Tumor | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583293 |
| 677 | = | Malignant Major Salivary Gland Neoplasm | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583307 |
| 677 | = | Malignant Sweat Gland Neoplasm | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583308 |
| 677 | = | Medulloblastoma Molecular Subtypes | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583309 |
| 677 | = | Myelodysplastic Syndrome Post Cytotoxic Therapy | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583310 |
| 677 | = | Myeloid Leukemia, Philadelphia-Positive | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583311 |
| 677 | = | Nasal Cavity Carcinoma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583321 |
| 677 | = | Neck Squamous Cell Carcinoma of Unknown Primary | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583322 |
| 677 | = | Non-Seminomatous Germ Cell Tumor | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583347 |
| 677 | = | Oropharynx Squamous Cell Carcinoma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583349 |
| 677 | = | Parathyroid Cancer | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583348 |
| 677 | = | Pleomorphic Rhabdomyosarcoma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583323 |
| 677 | = | Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583324 |
| 677 | = | Poorly Differentiated Thyroid Gland Carcinoma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583337 |
| 677 | = | Prostate Small Cell Neuroendocrine Carcinoma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583325 |
| 677 | = | Skin Nodular Basal Cell Carcinoma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583326 |
| 677 | = | Supratentorial Glioblastoma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583327 |
| 677 | = | Testicular Seminoma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583312 |
| 677 | = | Tongue Carcinoma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583338 |
| 677 | = | Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583328 |
| 677 | = | Urinary Tract Adenocarcinoma | 3 | 47 | Medium confidence | clinicaltrials | inputs
ranking row 2583329 |
| 743 | = | Acute Myeloid Leukemia Arising from Previous Myelodysplastic/Myeloproliferative Neoplasm | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583378 |
| 743 | = | Acute Myeloid Leukemia with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11 | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583484 |
| 743 | = | Acute Myeloid Leukemia with t(16;16)(p13.1;q22); CBFB-MYH11 | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583486 |
| 743 | = | Acute Myeloid Leukemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1 | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583485 |
| 743 | = | Adenocarcinoma with Neuroendocrine Differentiation | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583379 |
| 743 | = | Adult Gliosarcoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583416 |
| 743 | = | Adult Malignant Brain Neoplasm | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583454 |
| 743 | = | Alcohol-Related Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583351 |
| 743 | = | ALK-Positive Large B-Cell Lymphoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583455 |
| 743 | = | Alveolar Rhabdomyosarcoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583417 |
| 743 | = | Anal Canal Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583456 |
| 743 | = | Anaplastic Large Cell Lymphoma, ALK-Negative | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583380 |
| 743 | = | Anaplastic (Malignant) Meningioma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583356 |
| 743 | = | Anaplastic Oligoastrocytoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583357 |
| 743 | = | Bile Duct Adenocarcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583457 |
| 743 | = | BRCA Hereditary Breast Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583381 |
| 743 | = | Bronchogenic Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583382 |
| 743 | = | Burkitt Leukemia | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583358 |
| 743 | = | Cancer of Unknown Primary, NOS | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583490 |
| 743 | = | Castration-Resistant Prostate Adenocarcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583458 |
| 743 | = | Central Nervous System Leukemia | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583359 |
| 743 | = | Cerebral Glioblastoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583459 |
| 743 | = | Cervical Neuroendocrine Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583383 |
| 743 | = | Childhood B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583418 |
| 743 | = | Childhood Glioblastoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583384 |
| 743 | = | Childhood Hodgkin Lymphoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583385 |
| 743 | = | Childhood Malignant Thoracic Neoplasm | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583360 |
| 743 | = | Childhood Osteosarcoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583386 |
| 743 | = | Childhood Rhabdomyosarcoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583419 |
| 743 | = | Childhood WHO Grade 4 Glioma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583460 |
| 743 | = | Choriocarcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583361 |
| 743 | = | Choroid Plexus Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583387 |
| 743 | = | Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583420 |
| 743 | = | Colorectal Carcinoma with Genetic Abnormalities | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583461 |
| 743 | = | De Novo Myelodysplastic Syndrome | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583388 |
| 743 | = | Diffuse Large B-Cell Lymphoma Associated with Chronic Inflammation | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583462 |
| 743 | = | Diffuse Malignant Mesothelioma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583362 |
| 743 | = | Early T Precursor Acute Lymphoblastic Leukemia | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583421 |
| 743 | = | Early T Precursor Lymphoblastic Leukemia/Lymphoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583389 |
| 743 | = | Embryonal Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583363 |
| 743 | = | Embryonal Rhabdomyosarcoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583422 |
| 743 | = | Endometrial Dedifferentiated Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583463 |
| 743 | = | Endometrial Undifferentiated Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583423 |
| 743 | = | Eye Lymphoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583364 |
| 743 | = | Female Reproductive System Neuroendocrine Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583424 |
| 743 | = | Female Reproductive System Undifferentiated Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583390 |
| 743 | = | Folliculotropic Mycosis Fungoides | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583479 |
| 743 | = | Gallbladder Adenocarcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583464 |
| 743 | = | Ganglioneuroblastoma, Nodular | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583425 |
| 743 | = | Germ Cell Tumor of the Vulva | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583489 |
| 743 | = | Giant Cell Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583365 |
| 743 | = | Glottis Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583465 |
| 743 | = | Head and Neck Adenoid Cystic Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583391 |
| 743 | = | Head and Neck Mucosal Melanoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583366 |
| 743 | = | Hepatitis B Virus-Related Hepatocellular Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583426 |
| 743 | = | Hepatitis Virus-Related Hepatocellular Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583392 |
| 743 | = | Hepatosplenic T-Cell Lymphoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583427 |
| 743 | = | Hereditary Leiomyomatosis and Renal Cell Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583428 |
| 743 | = | High Grade B-Cell Lymphoma with MYC and BCL2 Rearrangements | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583487 |
| 743 | = | High Grade B-Cell Lymphoma with MYC and BCL6 Rearrangements | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583488 |
| 743 | = | High Grade Endometrioid Adenocarcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583393 |
| 743 | = | High Grade Sarcoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583367 |
| 743 | = | Histiocytic Sarcoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583368 |
| 743 | = | Human Papillomavirus-Independent Squamous Cell Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583394 |
| 743 | = | Human Papillomavirus-Related Adenocarcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583395 |
| 743 | = | Human Papillomavirus-Related Adenosquamous Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583429 |
| 743 | = | Human Papillomavirus-Related Cervical Adenocarcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583430 |
| 743 | = | Human Papillomavirus-Related Penile Squamous Cell Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583431 |
| 743 | = | Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583432 |
| 743 | = | Infratentorial Glioblastoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583433 |
| 743 | = | Intravascular Large B-Cell Lymphoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583466 |
| 743 | = | Invasive Bladder Giant Cell Urothelial Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583434 |
| 743 | = | Invasive Giant Cell Urothelial Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583396 |
| 743 | = | Kidney Carcinoma Molecular Subtypes | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583467 |
| 743 | = | Kidney Medullary Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583468 |
| 743 | = | Liver Lymphoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583397 |
| 743 | = | Liver Non-Hodgkin Lymphoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583435 |
| 743 | = | Low Grade Fibromyxoid Sarcoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583398 |
| 743 | = | Male Breast Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583399 |
| 743 | = | Malignant Brain Germ Cell Tumor | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583436 |
| 743 | = | Malignant Bronchial Neoplasm | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583369 |
| 743 | = | Malignant Central Nervous System Germ Cell Tumor | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583400 |
| 743 | = | Malignant Choroid Plexus Neoplasm | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583370 |
| 743 | = | Malignant Extragonadal Nongerminomatous Germ Cell Tumor | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583371 |
| 743 | = | Malignant Giant Cell Neoplasm | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583352 |
| 743 | = | Malignant Glottis Neoplasm | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583437 |
| 743 | = | Malignant Liver Non-Epithelial Neoplasm | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583438 |
| 743 | = | Malignant Mastocytosis | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583353 |
| 743 | = | Malignant Maxillary Sinus Neoplasm | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583439 |
| 743 | = | Malignant Ovarian Germ Cell Tumor | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583372 |
| 743 | = | Malignant Pineal Region Germ Cell Tumor | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583440 |
| 743 | = | Malignant Teratoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583373 |
| 743 | = | Malignant Testicular Non-Seminomatous Germ Cell Tumor | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583401 |
| 743 | = | Malignant Tonsillar Neoplasm | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583441 |
| 743 | = | Maxillary Sinus Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583469 |
| 743 | = | Medulloblastoma, Non-WNT/Non-SHH | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583442 |
| 743 | = | Microsatellite Stable Rectal Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583480 |
| 743 | = | Mixed Germ Cell Tumor | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583354 |
| 743 | = | Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583481 |
| 743 | = | Mycosis Fungoides Variant | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583470 |
| 743 | = | Myxoid Pleomorphic Liposarcoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583402 |
| 743 | = | Nasal Cavity Squamous Cell Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583471 |
| 743 | = | Nodal Peripheral T-Cell Lymphoma with TFH Phenotype | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583494 |
| 743 | = | Oligometastatic Adenocarcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583443 |
| 743 | = | Oligometastatic Prostate Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583444 |
| 743 | = | Oncocytic Adenocarcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583403 |
| 743 | = | Oral Cavity Verrucous Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583445 |
| 743 | = | Ovarian High Grade Endometrioid Adenocarcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583446 |
| 743 | = | Ovarian Sarcoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583404 |
| 743 | = | Pancreatic Acinar Cell Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583447 |
| 743 | = | Parathyroid Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583492 |
| 743 | = | Peripheral Primitive Neuroectodermal Tumor | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583374 |
| 743 | = | Plasmacytoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583375 |
| 743 | = | Pleural Diffuse Malignant Mesothelioma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583405 |
| 743 | = | Prefibrotic Primary Myelofibrosis | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583472 |
| 743 | = | Primary Cutaneous B-Cell Non-Hodgkin Lymphoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583448 |
| 743 | = | Primary Cutaneous Diffuse Large B-Cell Lymphoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583473 |
| 743 | = | Primary Effusion Lymphoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583406 |
| 743 | = | Primary Intraocular Non-Hodgkin Lymphoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583407 |
| 743 | = | Primary Malignant Neoplasm | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583355 |
| 743 | = | Prostate Adenocarcinoma with Neuroendocrine Differentiation | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583449 |
| 743 | = | Renal Medullary Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583493 |
| 743 | = | Renal Pelvis Urothelial Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583474 |
| 743 | = | Sclerosing Epithelioid Fibrosarcoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583408 |
| 743 | = | Solitary Plasmacytoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583409 |
| 743 | = | Superficial Basal Cell Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583450 |
| 743 | = | Supratentorial Gliosarcoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583475 |
| 743 | = | Sweat Gland Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583410 |
| 743 | = | Systemic Mastocytosis with an Associated Myeloid Neoplasm | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583411 |
| 743 | = | Thymus Neuroendocrine Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583412 |
| 743 | = | Thyroid Gland Oncocytic Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583376 |
| 743 | = | Tongue Squamous Cell Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583476 |
| 743 | = | Tonsillar Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583477 |
| 743 | = | Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583451 |
| 743 | = | Transplant-Related Malignant Neoplasm | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583377 |
| 743 | = | Urachal Adenocarcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583482 |
| 743 | = | Urachal Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583483 |
| 743 | = | Ureter Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583452 |
| 743 | = | Ureter Urothelial Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583478 |
| 743 | = | Uterine Corpus Leiomyosarcoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583453 |
| 743 | = | Vaginal Adenocarcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583413 |
| 743 | = | Verrucous Carcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583414 |
| 743 | = | Vulvar Adenocarcinoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583415 |
| 743 | = | Well-Differentiated Liposarcoma | 2 | 41.8 | Medium confidence | clinicaltrials | inputs
ranking row 2583491 |
| 887 | = | Acral Lentiginous Melanoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583771 |
| 887 | = | Acute Adult T-Cell Leukemia/Lymphoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583648 |
| 887 | = | Acute Bilineal Leukemia | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583772 |
| 887 | = | Acute Myeloid Leukemia with a Variant KMT2A Rearrangement | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583870 |
| 887 | = | Acute Myeloid Leukemia with Complex Karyotype | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583841 |
| 887 | = | Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11 | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583875 |
| 887 | = | Acute Myeloid Leukemia with Multilineage Dysplasia | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583773 |
| 887 | = | Acute Myeloid Leukemia with Myelodysplasia-Related Cytogenetic Abnormalities | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583774 |
| 887 | = | Adenosarcoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583501 |
| 887 | = | Adult Angiosarcoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583775 |
| 887 | = | Adult Diffuse Hemispheric Glioma, H3 G34-Mutant | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583776 |
| 887 | = | Adult Diffuse Midline Glioma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583547 |
| 887 | = | Adult Diffuse Midline Glioma, H3 K27-Altered | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583649 |
| 887 | = | Adult Diffuse Midline Glioma, H3 K27-Mutant | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583777 |
| 887 | = | Adult Medulloblastoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583548 |
| 887 | = | Adult Soft Tissue Sarcoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583549 |
| 887 | = | Adult T Acute Lymphoblastic Leukemia | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583650 |
| 887 | = | Aggressive Systemic Mastocytosis | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583550 |
| 887 | = | Aggressive Variant Prostate Carcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583842 |
| 887 | = | AIDS-Related Diffuse Large B-cell Lymphoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583651 |
| 887 | = | AIDS-Related Non-Hodgkin Lymphoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583551 |
| 887 | = | Alveolar Ridge Squamous Cell Carcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583778 |
| 887 | = | Anal Margin Carcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583552 |
| 887 | = | Anaplastic Astrocytoma, IDH-Wildtype | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583553 |
| 887 | = | Anaplastic Kidney Wilms Tumor | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583502 |
| 887 | = | Anaplastic Pleomorphic Xanthoastrocytoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583503 |
| 887 | = | Anorectal Melanoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583554 |
| 887 | = | Apocrine Carcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583652 |
| 887 | = | Appendix Mucinous Neoplasm | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583555 |
| 887 | = | Atypical Lipomatous Tumor | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583878 |
| 887 | = | B Acute Lymphoblastic Leukemia, BCR-ABL1-Like | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583779 |
| 887 | = | Barrett Adenocarcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583556 |
| 887 | = | Basal Ganglia Germinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583843 |
| 887 | = | B-Cell Prolymphocytic Leukemia | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583504 |
| 887 | = | BCLC Stage B Hepatocellular Carcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583780 |
| 887 | = | Biphasic Mesothelioma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583557 |
| 887 | = | Bladder Clear Cell Adenocarcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583781 |
| 887 | = | Bladder Large Cell Neuroendocrine Carcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583782 |
| 887 | = | Bladder Mixed Adenocarcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583844 |
| 887 | = | Bladder Neuroendocrine Carcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583654 |
| 887 | = | Bladder Small Cell Neuroendocrine Carcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583783 |
| 887 | = | B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583653 |
| 887 | = | Brain Germinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583784 |
| 887 | = | Brain Stem Glioblastoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583655 |
| 887 | = | BRCA Hereditary Ovarian Carcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583558 |
| 887 | = | Breast Ductal Carcinoma In Situ, Intermediate Grade | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583656 |
| 887 | = | Breast Ductal Carcinoma In Situ, Low Grade | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583657 |
| 887 | = | Breast Mixed Epithelial/Mesenchymal Metaplastic Carcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583658 |
| 887 | = | Breast Mucinous Carcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583659 |
| 887 | = | Breast Secretory Carcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583660 |
| 887 | = | Breast Tubular Carcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583661 |
| 887 | = | Buccal Mucosa Squamous Cell Carcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583785 |
| 887 | = | Carcinoma of Unknown Primary with Gastrointestinal Profile | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583662 |
| 887 | = | Central Nervous System Embryonal Tumor with Rhabdoid Features | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583505 |
| 887 | = | Central Nervous System Medulloepithelioma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583506 |
| 887 | = | Central Nervous System Non-Hodgkin Lymphoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583559 |
| 887 | = | Central Nervous System Yolk Sac Tumor | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583560 |
| 887 | = | Cerebellar Glioblastoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583786 |
| 887 | = | Cervical Cancer by FIGO Stage 2018 | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583787 |
| 887 | = | Cervical Esophagus Adenocarcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583788 |
| 887 | = | Cervical Small Cell Neuroendocrine Carcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583663 |
| 887 | = | Chemotherapy-Related Leukemia | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583561 |
| 887 | = | Childhood Acute Leukemia of Ambiguous Lineage | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583664 |
| 887 | = | Childhood Choroid Plexus Carcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583562 |
| 887 | = | Childhood Gliosarcoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583665 |
| 887 | = | Childhood Hepatocellular Carcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583563 |
| 887 | = | Childhood Intraocular Retinoblastoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583666 |
| 887 | = | Childhood Malignant Liver Neoplasm | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583564 |
| 887 | = | Childhood Myelodysplastic Syndrome | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583507 |
| 887 | = | Childhood Neuroblastic Tumor | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583565 |
| 887 | = | Childhood Neuroblastoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583667 |
| 887 | = | Childhood Pineoblastoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583566 |
| 887 | = | Childhood Primitive Neuroectodermal Tumor | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583508 |
| 887 | = | Childhood T Acute Lymphoblastic Leukemia | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583567 |
| 887 | = | Childhood T Lymphoblastic Leukemia/Lymphoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583509 |
| 887 | = | Choriocarcinoma Combined with Other Germ Cell Elements | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583510 |
| 887 | = | Chronic Adult T-Cell Leukemia/Lymphoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583668 |
| 887 | = | Chronic Myelomonocytic Leukemia-1 | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583669 |
| 887 | = | Chronic Neutrophilic Leukemia | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583568 |
| 887 | = | Colorectal Squamous Cell Carcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583569 |
| 887 | = | Combined Hepatocellular Carcinoma and Cholangiocarcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583570 |
| 887 | = | Conjunctival Melanoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583511 |
| 887 | = | Cribriform Carcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583571 |
| 887 | = | Cutaneous Follicular Lymphoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583572 |
| 887 | = | Cutaneous Spitz Melanoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583573 |
| 887 | = | Diffuse Pediatric-Type High Grade Glioma, H3-Wildtype and IDH-Wildtype | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583670 |
| 887 | = | Digestive System Follicular Lymphoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583574 |
| 887 | = | Digestive System Mucosal Melanoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583512 |
| 887 | = | Digestive System Small Cell Neuroendocrine Carcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583575 |
| 887 | = | Distal Bile Duct Adenocarcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583871 |
| 887 | = | Distal Esophagus Adenocarcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583789 |
| 887 | = | dMMR Colorectal Carcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583845 |
| 887 | = | Duodenal-Type Follicular Lymphoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583671 |
| 887 | = | Early Hepatocellular Carcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583790 |
| 887 | = | Early Stage HER2-Positive Breast Carcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583672 |
| 887 | = | Early Stage Lung Non-Small Cell Carcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583673 |
| 887 | = | EBV-Related Hodgkin Lymphoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583576 |
| 887 | = | Embryonal Tumor with Multilayered Rosettes, C19MC-Altered | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583577 |
| 887 | = | Endolymphatic Sac Tumor | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583674 |
| 887 | = | Endometrial Low Grade Endometrioid Adenocarcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583675 |
| 887 | = | Endometrial Mucinous Adenocarcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583676 |
| 887 | = | Epithelioid Mesothelioma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583578 |
| 887 | = | Esophageal Cancer by AJCC v8 Stage | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583677 |
| 887 | = | Esophageal Neuroendocrine Carcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583579 |
| 887 | = | Esophageal Small Cell Neuroendocrine Carcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583678 |
| 887 | = | Extragonadal Embryonal Carcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583580 |
| 887 | = | Extragonadal Germinomatous Germ Cell Tumor | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583581 |
| 887 | = | Extrahepatic Bile Duct Adenocarcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583846 |
| 887 | = | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue Involving the Digestive System | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583582 |
| 887 | = | Extranodal NK-/T-Cell Lymphoma, Nasal Type | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583882 |
| 887 | = | Extraocular Retinoblastoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583679 |
| 887 | = | Extrapulmonary Large Cell Neuroendocrine Carcinoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583680 |
| 887 | = | Extraskeletal Myxoid Chondrosarcoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583583 |
| 887 | = | Extraskeletal Osteosarcoma | 1 | 30.6 | Medium confidence | clinicaltrials | inputs
ranking row 2583584 |
Data updated 16 hours agoSource updated unknown1,277 eligible entities · inputs hash 4352f89d0670b61272a585b3